Seller: Zubal-Books, Since 1961, Cleveland, OH, U.S.A.
Condition: Good. 284 pp., Hardcover, ex library, else text clean and binding tight. - If you are reading this, this item is actually (physically) in our stock and ready for shipment once ordered. We are not bookjackers. Buyer is responsible for any additional duties, taxes, or fees required by recipient's country.
Language: English
Published by Worthing Baptist Church, United Kingdom, 1978
Seller: RIVERLEE BOOKS, Waltham Cross, HERTS, United Kingdom
US$ 14.82
Quantity: 1 available
Add to basketSoft cover. Condition: Good. Good for year paperback (staple binding): The book is in good readable condition 15 pages.
Language: English
Published by Quay Publishing, Lancaster, UK., 1992
ISBN 10: 1856420884 ISBN 13: 9781856420884
Seller: Tiber Books, Cockeysville, MD, U.S.A.
Hardcover. Condition: Very Good. 8vo, hardcover. No dj. Vg+ condition. Exterior faintly rubbed, contents bright, crisp & clean, virtually unopened. 286 pp.
Language: English
Published by Kluwer Academic Publishers, 1994
ISBN 10: 0792388720 ISBN 13: 9780792388722
US$ 20.72
Quantity: 1 available
Add to basketCloth/Laminated Boards. Condition: Very Good. Type: Book The timing of toxicological studies in relation to the clinical evaluation of new medicines is a key topic for strategic planners in the industry and those involved with harmonization. Resolving the anomalies between different regulatory authorities should eliminate redundant testing on animals and improve the efficiency of the developmental process by encouraging single international strategies. To aid industry in reaching a consensus, the Centre for Medicines Research has brought together representatives of the pharmaceutical industry from Europe, Japan and the USA to give a comprehensive account of current international industry positions on the subject. The contributions in this text review the situation and address the clinical and strategic requirements of the pre-clinical programme. Personal and consensus proposals on the toxicity studies required to initiate clinical investigations, the timing of reproductive toxicity tests and the duration of repeat-dose studies to support clinical development are provided. Small mark at base of spine.128pp.
Language: English
Published by Kluwer Academic Publishers, 1998
ISBN 10: 0792387317 ISBN 13: 9780792387312
US$ 27.62
Quantity: 1 available
Add to basketCloth/Laminated Boards. Condition: Very Good. Type: Book At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as "what target should be set for the review of new medicines?" and "how can quality be assured?" are now considered to be of critical importance. The 12th CMR International Workshop, held in January 1997, provided the opportunity for regulatory authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarizes the many suggestions that were debated at the workshop, and includes chapters on measuring performance, and on the integration of quality into the review process. 163pp.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 68.09
Quantity: Over 20 available
Add to basketCondition: New. In.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 68.09
Quantity: Over 20 available
Add to basketCondition: New. In.
Seller: Chiron Media, Wallingford, United Kingdom
US$ 65.87
Quantity: 10 available
Add to basketPaperback. Condition: New.
Seller: Chiron Media, Wallingford, United Kingdom
US$ 65.96
Quantity: 10 available
Add to basketPaperback. Condition: New.
Seller: Revaluation Books, Exeter, United Kingdom
US$ 89.09
Quantity: 2 available
Add to basketPaperback. Condition: Brand New. 1997 edition. 163 pages. 9.45x6.30x0.43 inches. In Stock.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 105.40
Quantity: Over 20 available
Add to basketCondition: New. In.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 105.40
Quantity: Over 20 available
Add to basketCondition: New. In.
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition.
Language: English
Published by Springer Netherlands, Springer Netherlands, 2012
ISBN 10: 9401060428 ISBN 13: 9789401060424
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as 'what target should be set for the review of new medicines ' and `how can quality be assured ' are now considered to be of critical importance. The twelfth CMR International Workshop, held in January 1997, provided the opportunity for Regulatory Authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarises the many suggestions that were debated at the Workshop, and includes chapters on measuring performance, and on the integration of quality into the review process.
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - For a research-based pharmaceutical company to be successful in the 1990s. it must have a strategic plan for the global development of new chemical entities. Global development can be defined as an attempt to reach all major markets as rapidly as possible and for many companies these will include the United States. Japan. Germany. France. Italy. UK and Canada. which together represent approximately 85% of the pharmaceutical market in the developed world. The mutual acceptance of foreign clinical data would reduce the time and resources required to develop a new medicine for the international market by eliminating the requirement for the routine repetition of clinical studies in local populations. In Japan this has been largely based on the belief that genetic differences in respon siveness may result in a different benefit/risk assessment for a new mediCine. while requests in Europe and the United States for local data relate mainly to methodological and cultural considerations. The importance of this issue has been recognised internationally as it was one of the topics discussed at the International Conference on Harmonisation in Orlando (October 1993) and it is currently on the programme for ICH3 which will be convened in Yokohama in Japan in November 1995.
Taschenbuch. Condition: Neu. The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines | Proceedings of a Workshop held at The Medical Society of London, UK, 7th and 8th July, 1993 | S. R. Walker (u. a.) | Taschenbuch | xviii | Englisch | 2012 | Springer | EAN 9789401046213 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Seller: preigu, Osnabrück, Germany
Taschenbuch. Condition: Neu. Improving the Regulatory Review Process: Assessing Performance and Setting Targets | N. McAuslane (u. a.) | Taschenbuch | xix | Englisch | 2012 | Springer | EAN 9789401060424 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 130.25
Quantity: Over 20 available
Add to basketCondition: New. In.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
US$ 130.69
Quantity: Over 20 available
Add to basketCondition: New. In.
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New.
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
US$ 130.68
Quantity: Over 20 available
Add to basketCondition: New.
Seller: Mispah books, Redhill, SURRE, United Kingdom
US$ 122.93
Quantity: 1 available
Add to basketPaperback. Condition: Like New. Like New. book.
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
US$ 147.68
Quantity: Over 20 available
Add to basketCondition: As New. Unread book in perfect condition.
Language: English
Published by Kluwer Academic Publishers, 1995
ISBN 10: 0792388720 ISBN 13: 9780792388722
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Ireland
Condition: New. The timing of toxicological studies in relation to the clinical evaluation of new medicines is a key topic for strategic planners in the industry and those involved with harmonisation. This book reviews the situation and addresses the clinical and strategic requirements of the preclinical programme. Editor(s): Parkinson, C. Num Pages: 150 pages, biography. BIC Classification: MMG; TDCW. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 234 x 156 x 11. Weight in Grams: 930. . 1995. Hardback. . . . .
Seller: Revaluation Books, Exeter, United Kingdom
US$ 159.74
Quantity: 2 available
Add to basketHardcover. Condition: Brand New. 188 pages. 6.14x0.50x9.21 inches. In Stock.
Seller: Revaluation Books, Exeter, United Kingdom
US$ 161.55
Quantity: 2 available
Add to basketHardcover. Condition: Brand New. 1st edition. 262 pages. 9.75x6.50x1.00 inches. In Stock.
Language: English
Published by Springer Netherlands|Springer, Berlin, 1998
ISBN 10: 0792387317 ISBN 13: 9780792387312
Seller: moluna, Greven, Germany
US$ 124.12
Quantity: Over 20 available
Add to basketCondition: New. At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiv.
Language: English
Published by Springer Netherlands|Springer, Berlin, 1994
ISBN 10: 0792388437 ISBN 13: 9780792388432
Seller: moluna, Greven, Germany
US$ 124.12
Quantity: Over 20 available
Add to basketCondition: New. There is currently limited acceptance of foreign clinical data by regulatory authorities, although the reasons for repeating studies are poorly defined. There are some proven genetic differences in drug metabolism and elimination which occur with varying fr.
Seller: AHA-BUCH GmbH, Einbeck, Germany
Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - At a time when it is becoming usual for medicines to be developed for a global market and pharmaceutical companies are endeavouring to expedite the drug development process, Regulatory Authorities are concentrating on improving their efficiency and effectiveness. Therefore, it is not surprising that questions are being asked as to how performance might be measured and compared between different authorities who are now often in receipt of dossiers that have been submitted to several agencies at the same time. Issues such as 'what target should be set for the review of new medicines ' and `how can quality be assured ' are now considered to be of critical importance. The twelfth CMR International Workshop, held in January 1997, provided the opportunity for Regulatory Authority and industry personnel from Europe, North America, Australia and Japan to openly discuss experiences and exchange views on how to improve the review process. The proceedings of this meeting provide a comprehensive overview of the current review process in different countries and the need for performance measures and targets. This volume summarises the many suggestions that were debated at the Workshop, and includes chapters on measuring performance, and on the integration of quality into the review process.